High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis

Background. We aimed to evaluate the correlation of platelet-to-lymphocyte ratio (PLR) with prognosis and clinicopathological characteristics of breast cancer. Methods. The PubMed and Embase databases were searched. Hazard ratio (HR) with 95% confidence interval (CI) was used to summarize disease-fr...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2017-01, Vol.2017 (2017), p.1-11
Main Authors: Sun, Jing-xu, Gao, Peng, Song, Yong-xi, Huang, Xuan-zhang, Zhang, Miao, Wang, Zhen-ning
Format: Article
Language:English
Subjects:
Blood platelets
Blood Platelets - pathology
Breast cancer
Breast Neoplasms - blood
Breast Neoplasms - pathology
Cancer
Cancer therapies
Chemotherapy
Confidence intervals
Disease-Free Survival
Female
Health aspects
Hospitals
Humans
Incidence
Inflammation
Lymph
Lymph nodes
Lymphocyte Count
Lymphocytes
Lymphocytes - pathology
Medical prognosis
Medical research
Meta-analysis
Metastases
Patients
Platelet Count
Platelets
Prognosis
Review
Studies
Survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. We aimed to evaluate the correlation of platelet-to-lymphocyte ratio (PLR) with prognosis and clinicopathological characteristics of breast cancer. Methods. The PubMed and Embase databases were searched. Hazard ratio (HR) with 95% confidence interval (CI) was used to summarize disease-free survival (DFS) and overall survival (OS). Odds ratio (OR) was used to summarize tumor clinicopathological characteristics. Results. High PLR was associated with poor DFS and OS (DFS: HR = 1.47, 95% CI = 1.16–1.85, and Tau2 = 0.070; OS: HR = 1.88, 95% CI = 1.27–2.80, and Tau2 = 0.192). A Galbraith plot indicated that the studies by Allan et al. and Cihan et al. contributed the heterogeneity of DFS and OS, respectively. There were significant differences in the incidence of high PLR between stage II–IV and stage I groups (OR = 1.86, 95% CI = 1.20–2.90, and Tau2 < 0.001), between lymph node-positive and lymph node-negative groups (OR = 1.52, 95% CI = 1.22–1.91, and Tau2 =0.014), and between metastasis-positive and metastasis-negative groups (OR = 4.24, 95% CI = 2.73–6.59, and Tau2 < 0.001). Conclusions. Our results indicated that PLR was associated with poor prognosis of breast cancer and adequately predicted clinicopathological characteristics.
ISSN:2314-6133
2314-6141
DOI:10.1155/2017/9503025